Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts

Methodology, criteria and characterization of patient-matched thyroid cell lines and... Abstract Objective In order to investigate the molecular underpinnings of thyroid cancer, preclinical cell line models are crucial; however, ∼40% of these have been proven to be either duplicates of existing thyroid lines or even non-thyroid derived lines or are not derived from human at all. Therefore, we set out to establish procedures and guidelines that should proactively avoid these problems, which facilitated the creation of criteria to make valid pre-clinical models for thyroid cancer research. Design Based upon our recommendations, we systematically characterized all new cell lines that we generated by a standardized approach that included (i) determination of human origin, (ii) exclusion of lymphoma, (iii) DNA fingerprinting and histological comparisons to establish linkage to presumed tissue of origin, (iv) examining thyroid differentiation by screening 2-3 thyroid markers, (v) examination of biological behavior (growth rate, tumorigenicity) and (vi) presence of common thyroid cancer genetic changes (TP53, BRAF, PTEN, PIK3CA, RAS, TERT promoter, RET/PTC, PAX8/PPARγ, NF1 and EIF1AX). Results We established 7 new thyroid cell lines (LAM136, EAM306, SDAR1, SDAR2, JEM493, THJ529, and THJ560) out of 294 primary culture attempts, and 10 patient-derived tumor xenografts (PDTX; MC-Th-95, MC-Th-374, MC-Th-467, MC-Th-491, MC-Th-493, MC-Th-504, MC-Th-524, MC-Th-529, MC-Th-560, MC-Th-562) out of 67 attempts. All were successfully validated by our protocols. Conclusions This standardized approach for cell line and PDTX characterization should prevent (or detect) future cross-contamination and ensure that only valid preclinical models are used for thyroid cancer research. Copyright © 2018 Endocrine Society http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Endocrinology and Metabolism Oxford University Press

Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts

Loading next page...
 
/lp/ou_press/methodology-criteria-and-characterization-of-patient-matched-thyroid-rfCLjsnO9o
Publisher
Endocrine Society
Copyright
Copyright © 2018 Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
D.O.I.
10.1210/jc.2017-01845
Publisher site
See Article on Publisher Site

Abstract

Abstract Objective In order to investigate the molecular underpinnings of thyroid cancer, preclinical cell line models are crucial; however, ∼40% of these have been proven to be either duplicates of existing thyroid lines or even non-thyroid derived lines or are not derived from human at all. Therefore, we set out to establish procedures and guidelines that should proactively avoid these problems, which facilitated the creation of criteria to make valid pre-clinical models for thyroid cancer research. Design Based upon our recommendations, we systematically characterized all new cell lines that we generated by a standardized approach that included (i) determination of human origin, (ii) exclusion of lymphoma, (iii) DNA fingerprinting and histological comparisons to establish linkage to presumed tissue of origin, (iv) examining thyroid differentiation by screening 2-3 thyroid markers, (v) examination of biological behavior (growth rate, tumorigenicity) and (vi) presence of common thyroid cancer genetic changes (TP53, BRAF, PTEN, PIK3CA, RAS, TERT promoter, RET/PTC, PAX8/PPARγ, NF1 and EIF1AX). Results We established 7 new thyroid cell lines (LAM136, EAM306, SDAR1, SDAR2, JEM493, THJ529, and THJ560) out of 294 primary culture attempts, and 10 patient-derived tumor xenografts (PDTX; MC-Th-95, MC-Th-374, MC-Th-467, MC-Th-491, MC-Th-493, MC-Th-504, MC-Th-524, MC-Th-529, MC-Th-560, MC-Th-562) out of 67 attempts. All were successfully validated by our protocols. Conclusions This standardized approach for cell line and PDTX characterization should prevent (or detect) future cross-contamination and ensure that only valid preclinical models are used for thyroid cancer research. Copyright © 2018 Endocrine Society

Journal

Journal of Clinical Endocrinology and MetabolismOxford University Press

Published: May 25, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off